Charles River Laboratories International is cutting over 600 jobs, citing softening demand from pharmaceutical clients.

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Charles River Labs (CRL – Research Report) today and set a price ...

To begin with, Charles River Laboratories International seems to have a respectable ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 12%. This ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $218.3, with a ...

Just a few months after the reveal of Ori Biotech’s automated cell and gene therapy manufacturing platform IRO, the technical ...

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...

Charles River Lbrtrs ntrntl Inc (CRL) stock saw a decline, ending the day at $200.62 which represents a decrease of $-3.15 or -1.55% from the prior close of $203.77. The stock opened at $205.01 and ...

Charles River Laboratories International, Inc. CRL and CEBINA GmbH (Central European Biotech Incubator and Accelerator) have formed a strategic alliance under the DanubeNeuro acceleration program — an ...

Charles River and CEBINA will accelerate innovative approaches to treating neurodegenerative diseases Charles River Laboratories International, Inc. (NYSE: CRL) and CEBINA GmbH, Central European ...

Toxic algae blooms composed of cyanobacteria are affecting parts of the Charles River right now. When will it be safe? Here's ...

Charles River announces strategic collaboration with CEBINA to accelerate neuroscience research, advancing innovative projects & technologies.